10x Genomics, Inc. (TXG)

10x Genomics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	502.51	473.97	344.07	359.28	219.75	587.45
Short-Term Investments	49.52	49.44	49.34	29.41	210.24	-
Cash & Short-Term Investments	552.03	523.41	393.4	388.7	429.98	587.45
Cash Growth	23.43%	33.05%	1.21%	-9.60%	-26.80%	-11.48%
Accounts Receivable	47.55	47.01	87.86	114.83	104.21	85.25
Other Receivables	3.08	35.48	0.61	-	-	-
Receivables	50.63	82.49	88.47	114.83	104.21	85.25
Inventory	52.62	56.34	83.11	73.71	81.63	59.97
Prepaid Expenses	19.39	22.21	19.41	18.79	16.58	13.9
Restricted Cash	-	-	-	-	2.63	1.03
Total Current Assets	674.67	684.45	584.39	596.02	635.04	747.59
Property, Plant & Equipment	272.01	287.16	309.94	344.93	359.21	230.41
Goodwill	6.92	4.51	4.51	4.51	4.51	4.51
Other Intangible Assets	61.16	62.33	15.67	16.62	22.86	25.4
Other Long-Term Assets	15.31	2.91	4.13	3.06	7.37	10.92
Total Assets	1,030	1,041	918.64	965.14	1,029	1,019

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	20.69	12.73	12.91	15.74	21.6	17.35
Accrued Expenses	34.59	51.89	52.07	45.98	51.9	53.27
Current Portion of Leases	12.02	10.99	9.29	11.52	9.04	5.13
Current Income Taxes Payable	6.95	7.22	4.94	5.05	4.08	4.62
Current Unearned Revenue	23.61	23.9	20.66	13.15	7.87	5.34
Other Current Liabilities	20.66	46.73	17.77	35.73	36.48	24.64
Total Current Liabilities	118.51	153.45	117.63	127.16	130.96	110.36
Long-Term Leases	66.78	73.38	73.33	83.85	86.14	76.85
Long-Term Unearned Revenue	9.68	10.5	12.51	8.81	3.17	-
Other Long-Term Liabilities	9.55	7.71	5.03	4.28	2.98	14.05
Total Liabilities	204.52	245.04	208.5	224.1	223.24	201.26

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	2,367	2,307	2,178	2,026	1,839	1,681
Retained Earnings	-1,542	-1,511	-1,467	-1,284	-1,029	-863.32
Comprehensive Income & Other	0.08	0.23	-0.49	-0.43	-4.34	0.02
Total Common Equity	825.55	796.33	710.13	741.04	805.74	817.57
Shareholders' Equity	825.55	796.33	710.13	741.04	805.74	817.57
Total Liabilities & Equity	1,030	1,041	918.64	965.14	1,029	1,019

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	78.8	84.36	82.61	95.37	95.18	81.98
Net Cash (Debt)	473.24	439.05	310.79	293.33	334.81	505.47
Net Cash Growth	31.27%	41.27%	5.95%	-12.39%	-33.76%	-15.84%
Net Cash Per Share	3.71	3.52	2.58	2.50	2.94	4.58
Filing Date Shares Outstanding	130.29	127.75	122.3	119.17	115.36	112.84
Total Common Shares Outstanding	130.28	127.69	122.29	119.1	115.2	112.51
Working Capital	556.16	531	466.75	468.86	504.08	637.23
Book Value Per Share	6.34	6.24	5.81	6.22	6.99	7.27
Tangible Book Value	757.47	729.49	689.95	719.92	778.37	787.66
Tangible Book Value Per Share	5.81	5.71	5.64	6.04	6.76	7.00
Land	36.77	36.77	36.77	36.77	36.78	36.1
Buildings	147.61	147.49	147.09	146.04	-	-
Machinery	106.24	103.26	97.04	96.6	76.87	62.69
Construction In Progress	2.07	2.93	5.15	7.25	153	52.19
Leasehold Improvements	90.4	89.72	89.57	96.41	91.52	67.53

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 14, 2026

Data Sources Report a data error